- Adherence is a critical issue to address in patients who are prescribed metformin.
- Sulfonylureas are still recommended as a standard initial option for addition to metformin.
- Treatment algorithms reflect the complexity of treatment decisions but offer consistent guidance on a stepped/progressive approach to blood glucose control.
Clinical e-Audit for GPs – Type 2 diabetes and CVD: managing the risk
Improve health outcomes for your patients with both type 2 diabetes and cardiovascular disease (CVD) by familiarising yourself with the latest CV outcome data and increasing your confidence to navigate management choices for the condition.
This Clinical e-Audit requires data to be submitted for only SEVEN (7) patients.
This program is funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.
Webinar: CV risk in patients with type 2 diabetes and CVD: Getting to the heart of diabetes
Listen to our multidisciplinary panel of experts discuss the prevention of CV events in patients with both type 2 diabetes and CVD. Discussion covers:
- Evidence-based strategies to reduce CV risk for patients with diabetes and CVD
- Advice on how to individualise choice of blood glucose-lowering agents
- The latest Australian blood glucose treatment algorithm for type 2 diabetes
- An update on the latest CV outcome trial data and how this impacts your practice
This program was funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.
Australian Prescriber: Second steps in managing type 2 diabetes
Dr Carolyn Petersons
Aust Prescr 2018;41:141-4
Metformin is still first choice for type 2 diabetes, but what comes next? In the October 2018 issue of Australian Prescriber, Dr Carolyn J Petersons sorts out the second steps in managing type 2 diabetes.
Episode 36 – Dhineli Perera interviews Dr Carolyn Petersons about the second- and third-line drugs for type 2 diabetes. After metformin, what comes next?
Empagliflozin indications extended
Empagliflozin is now TGA-approved for reducing cardiovascular deaths in patients with type 2 diabetes with established cardiovascular disease.
What is the evidence, and what does this mean in clinical practice?
NPS RADAR: Insulin glargine 300 IU/mL solution (Toujeo) for diabetes mellitus
Insulin glargine 300 IU/mL (Gla-300) solution is another option for adults with type 1 or type 2 diabetes requiring a long-acting basal insulin. Gla-300 is a concentrated formulation of the PBS-listed Gla-100.
MedicineWise News: Type 2 diabetes – when metformin is not enough
Sulfonylureas are the usual add-on treatment when metformin is no longer sufficient, but are they the best? Review the evidence on efficacy, safety and outcomes for second-line type 2 diabetes treatments.
NPS RADAR: Pharmacological therapies in Australia for type 2 diabetes
Metabolic syndrome and diabetes: how much blame does sugar deserve?
An increasing number of journal articles and media stories are highlighting the potential role of dietary sugar, and particularly added fructose, as a major contributor to ill health, from cardiovascular disease to type 2 diabetes to metabolic syndrome.
Australian Prescriber: Encouraging adherence to long‑term medication
Aust Prescr 2017;40:147-501
Patients should be asked about adherence at every consultation.
Learn more about:
- using a collaborative communication style
- using the patient’s own expressions and responding to their cues
- how to normalise non-adherence
- using open questions and more specific probes.
Episode 6 – Encouraging adherence to long-term medication, with Prof Tim Usherwood
Dr Janine Rowse interviews Professor Tim Usherwood about the different types of medication non-adherence and his practical recommendations for better identification in the primary care setting.
Consolidate your knowledge about type 2 diabetes, brush up on current guidelines and practices and earn CPD points through our learning activities.